Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ARHGAP26
REST API REST API
Homo sapiens
ARHGAP26 is differentially expressed in 302 experiments: 149 organism parts: placenta, lung, ... (147 more);, 239 disease states: normal, control, ... (237 more);, 117 cell types 427 cell lines 47 compound treatments and 77 other conditions.
Synonyms OPHN1L, GRAF, OPHN1L1, KIAA0621
Orthologs Arhgap26 (Mus musculus)   ARHGAP26 (Gallus gallus)   BEM2 (Saccharomyces cerevisiae)   ENSCING00000003601 (Ciona intestinalis)   ARHGAP26 (Bos taurus)   Arhgap26 (Rattus norvegicus)   Graf (Drosophila melanogaster)   arhgap26 (Xenopus laevis)   ARHGAP26 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term focal adhesion, cytosol, protein binding, cytoskeleton, cytoplasm, intracellular, SH3 domain binding, cell junction, GTPase activator activity, actin cytoskeleton organization, small GTPase mediated signal transduction, filopodium assembly, regulation of small GTPase mediated signal transduction, cellular_component, nervous system development, cytoskeletal adaptor activity, signal transduction, Rho GTPase activator activity, positive regulation of Rho GTPase activity
InterPro Term SH3_domain, IRSp53/MIM_homology_IMD, Pleckstrin_homology, SH3_2, RhoGAP_dom
UniProt Accession Q9UNA1, C9J6V4, Q9HBW4, Q8NFJ1, D9ZGG7, F8W9V9, F8W8N5
Gene-Disease Assocation JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML
Search EB-eye ENSG00000145819
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-7224, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-MTAB-62, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
MDA468
2
E-MEXP-440, E-MTAB-62
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
GM15510
2
E-GEOD-19466, E-GEOD-22639
421 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (58 experiments)

Factor Value U/D Experiments
monocyte
2
4
E-MEXP-583, E-GEOD-22373, E-GEOD-5099, E-GEOD-11755, E-GEOD-8286, ... (6 experiments)
plasma cell
2
E-MEXP-2360, E-GEOD-6691
fibroblast
2
E-GEOD-3920, E-GEOD-3204
2
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
111 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-TABM-15, E-MEXP-2280, ... (62 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
control
1
3
E-GEOD-21912, E-GEOD-20295, E-GEOD-8121, E-GEOD-16363
leiomyosarcoma
2
E-MEXP-1922, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
233 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-5824, E-GEOD-7708, E-TABM-868, E-MEXP-1958, ... (29 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
dihydrotestoterone
1
E-GEOD-7708
chloroguine
1
E-GEOD-5418
baseline sevoflurane
1
E-GEOD-4386
interleukin-26 (Homo sapiens)
1
E-GEOD-7216
41 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-MEXP-2283, E-MEXP-958, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (7 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-22593, E-GEOD-18736, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-MEXP-1273, E-GEOD-20505, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-20876, E-GEOD-16363, ... (31 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-17400, E-GEOD-6802

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Library source
studied in E-GEOD-19323

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-4600, ... (6 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-12293, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Processing time: 0.31 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM